The MYC-affected downstream pathways include the B cell receptor signaling (37), which implies a possible interference with Bruton tyrosine kinase inhibitors and conceivably challenging treatment of CLL patients with MYC abnormalities. Here, MYC is linked to B-cell chronic lymphocytic leukemia.